Choosing the right lung cancer cell line is one of the most consequential decisions you will make at the start of a study. The cell line you pick shapes everything downstream, how your drug candidates behave, what mutations you can study, whether your results will translate to an in vivo setting, and how your data will be interpreted when it reaches publication.
This guide is written for researchers who already understand basic cell culture and want practical, direct guidance on which lung cancer cell lines are best suited for specific research applications, and why.
Understanding Lung Cancer Subtypes and Why They Matter for Cell Line Selection
Lung cancer is not a single disease. It is a collection of molecularly distinct cancers that happen to originate in the lung, and the cell line you choose must reflect the subtype you are studying.
Non-small cell lung cancer (NSCLC) accounts for roughly 85% of all lung cancers. It includes three main histological subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each has a distinct molecular profile, and the cell lines used to model each subtype differ accordingly.
Small cell lung cancer (SCLC) makes up the remaining 15%. It is a neuroendocrine tumor, grows aggressively, responds initially to chemotherapy but almost always develops resistance, and has a very different biological character from NSCLC. The cell lines used to model SCLC are not interchangeable with NSCLC models.
Before you select a cell line, clarify which subtype, which mutation, and which clinical scenario you are trying to model. That single question will narrow your options considerably.
Most Commonly Used Human Lung Cancer Cell Lines
A549: The Default NSCLC Workhorse
A549 is derived from a human lung adenocarcinoma and is, by a wide margin, the most frequently used lung cancer cell line in the world. It grows as an adherent monolayer, is straightforward to culture, and is compatible with almost every standard assay.
A549 carries a homozygous KRAS G12S mutation and wild-type EGFR. This mutation profile makes it a useful model for studying KRAS-driven oncogenesis, but it also means A549 is intrinsically resistant to EGFR-targeted tyrosine kinase inhibitors (TKIs). If your research involves EGFR-targeted therapy, A549 is the wrong choice.
Its greatest strengths are accessibility, reproducibility, and its long track record in the literature. It is available from ATCC and is a reliable baseline for toxicology, cytotoxicity, and general NSCLC biology work.
H1299: A p53-Null Adenocarcinoma Line
NCI-H1299 is a human lung adenocarcinoma cell line established from a lymph node metastasis. Its defining molecular feature is that it is p53-null — a rare characteristic among commonly used lung cancer cell lines that makes it specifically valuable for p53-related research.
If you are studying the role of p53 in lung cancer, investigating p53-dependent apoptosis pathways, or comparing p53 wild-type versus null backgrounds, H1299 fills a niche that most other cell lines cannot.
H1299 is also EGFR wild-type and KRAS wild-type, making it a relatively clean background for genetic manipulation studies where you want to introduce specific mutations without pre-existing driver oncogene interference.
PC9: The Reference Line for EGFR Exon 19 Deletion
PC9 is a human lung adenocarcinoma cell line with an EGFR exon 19 deletion (del E746-A750). This is one of the two most common sensitizing EGFR mutations seen in clinical NSCLC patients, particularly in East Asian populations and non-smokers.
PC9 is highly sensitive to first-generation EGFR TKIs such as gefitinib and erlotinib, as well as second-generation and third-generation agents including osimertinib. It is the standard model for validating EGFR-targeted therapies and for studying acquired resistance mechanisms that emerge following TKI treatment.
When researchers want to model what happens clinically in EGFR-mutant NSCLC patients, PC9 is typically the first choice.
HCC827: Another EGFR-Mutant Line with Distinct Biology
Like PC9, HCC827 carries an EGFR exon 19 deletion and responds to EGFR TKIs. However, the two lines are not biologically identical and should not be treated as interchangeable.
HCC827 was derived from a different patient background and can behave differently in resistance studies. For instance, responses to cetuximab, hypoxia-driven resistance, and exosome-mediated effects differ between HCC827 and PC9 despite their shared mutation. Using both lines in parallel is a recognized approach in EGFR resistance research because it provides stronger evidence than relying on a single cell line.
H1975: Modeling Acquired Resistance to First-Generation TKIs
NCI-H1975 carries two EGFR mutations simultaneously: L858R (a sensitizing mutation) and T790M (the most common acquired resistance mutation). T790M develops in roughly 50 to 60% of patients who become resistant to first-generation EGFR TKIs.
H1975 is the go-to cell line for studying T790M-driven resistance and for evaluating third-generation EGFR inhibitors such as osimertinib, which was specifically designed to overcome this resistance mechanism. H1975 does not respond to gefitinib or erlotinib, which distinguishes it functionally from PC9 and HCC827 despite also being EGFR-mutant.
H460: Large Cell Lung Carcinoma with Wild-Type EGFR
NCI-H460 is classified as a large cell lung carcinoma — the rarest and least differentiated NSCLC subtype. It carries a PIK3CA mutation and wild-type EGFR, grows robustly, and is commonly used in drug cytotoxicity studies, tumor xenograft models, and PI3K pathway research.
H460 is notable for its rapid growth and consistent engraftment in xenograft experiments, making it useful when in vivo tumor growth kinetics are a priority in the study design.
EGFR Mutation Status: Why It Defines Your Cell Line Decision
If your research involves EGFR-targeted therapy — which encompasses a large proportion of current NSCLC drug development — mutation status is the primary selection criterion.
The landscape breaks down as follows:
EGFR wild-type cells such as A549 and H1299 are resistant to first, second, and third-generation TKIs and serve as negative controls or models for EGFR-independent biology.
EGFR exon 19 deletion lines such as PC9 and HCC827 are sensitive to gefitinib, erlotinib, afatinib, and osimertinib. They represent the patient population that initially responds to TKI therapy.
EGFR T790M-positive lines such as H1975 are resistant to first-generation TKIs but respond to osimertinib. They model the most common acquired resistance scenario seen in the clinic.
Matching your cell line's mutation profile to your scientific question is not optional — it is the foundation of valid experimental design.
Small Cell Lung Cancer Cell Lines
SCLC research uses a distinct set of cell lines. The most commonly used human SCLC lines include H69, H446, SHP-77, and H1048. These are largely suspension or loosely adherent cell lines that reflect the neuroendocrine origin of SCLC and its characteristic biology.
SCLC cell lines are biologically different from NSCLC models in several important ways: they tend to have near-universal RB1 inactivation, frequent TP53 mutations, and high sensitivity to platinum-based chemotherapy paired with etoposide — the standard first-line treatment regimen.
One challenge in SCLC research is the development of chemotherapy resistance, which is rapid and almost universal. Cell lines derived from patients following progression on platinum-etoposide treatment can model this acquired chemoresistance and are used to study second-line treatment strategies.
If your research concerns SCLC, do not attempt to extrapolate results from NSCLC cell lines. The two are biologically distinct enough that findings rarely cross over.
Mouse and Murine Lung Cancer Cell Lines
Lewis Lung Carcinoma (LLC)
The Lewis Lung Carcinoma cell line, commonly referred to as LLC, is the most widely used syngeneic murine lung cancer model. Derived originally from a spontaneous carcinoma in a C57BL/6 mouse, it is immunologically compatible with C57BL/6 mice and can therefore be implanted into immunocompetent hosts.
This is the LLC model's defining advantage: because it grows in immune-competent animals, it preserves the interaction between tumor and immune system that immunodeficient xenograft models cannot replicate. This makes it the standard model for studying immunotherapy combinations, tumor immunity, and the tumor microenvironment in lung cancer.
LLC carries mutations in Kras and Nras, along with TP53 alterations, but its genomic profile is not comparable to human NSCLC. Findings in LLC should be interpreted in the context of its murine background rather than directly extrapolated to human biology.
Syngeneic Models Beyond LLC
Other murine lung cancer cell lines such as 393P (a non-metastatic syngeneic line) and LL2 are used in specific research settings where metastatic behavior, immune profiling, or genetic manipulation in a mouse background is required. The choice between these lines typically depends on whether the study requires metastatic potential and which murine strain is used in the laboratory.
Practical Framework: Matching Your Research Goal to the Right Cell Line
The following gives you a direct starting point for common research scenarios:
Studying basic NSCLC cytotoxicity or general drug effects A549 is the standard starting point due to its reproducibility and established literature baseline.
Investigating EGFR-targeted therapies, first-generation TKIs Use PC9 or HCC827 as sensitive lines, and A549 or H1299 as resistant controls.
Modeling acquired TKI resistance via T790M H1975 is the primary model. Comparing H1975 to PC9 directly illustrates the sensitivity-to-resistance transition.
p53-focused research H1299 (p53-null) provides a clean background. Compare with A549 (p53 wild-type) where a paired comparison is needed.
KRAS mutation research A549 (KRAS G12S) is the most accessible starting point; however, be aware that KRAS-mutant NSCLC is notoriously resistant to most targeted agents and results are often difficult to translate.
Tumor immunology or immunotherapy studies in vivo The LLC model in C57BL/6 mice is the conventional choice for syngeneic immune-competent experiments.
SCLC research — Select from established SCLC-specific lines such as H69, H446, or SHP-77 rather than adapting NSCLC lines.
Important Caveats When Working with Established Cell Lines
Established cell lines are powerful tools, but they carry inherent limitations that every researcher should account for.
Cell lines drift from their original characteristics over serial passage. Cultures maintained at high passage numbers may exhibit altered gene expression, reduced drug sensitivity, or loss of key mutations compared to early-passage stocks. Always obtain authenticated, low-passage cells from a reputable repository such as ATCC or DSMZ, and record passage numbers in your methods.
Cross-contamination between cell lines remains a real problem in many laboratories. Ensure that the cells you are working with are what you believe them to be by requesting STR authentication data or performing in-house authentication.
Frequently Asked Questions
What are the most common lung cancer cell lines used in research?
The most commonly used human lung cancer cell lines are A549, H1299, PC9, HCC827, H1975, and H460 for NSCLC, and H69, H446, and SHP-77 for SCLC. A549 is the single most frequently cited cell line across the broader lung cancer research literature due to its ease of culture and availability.
What is the A549 lung cancer cell line used for?
A549 is a human lung adenocarcinoma cell line derived from alveolar carcinoma tissue. It is widely used for cytotoxicity assays, drug screening, KRAS biology studies, nanoparticle toxicity testing, and as a general NSCLC model.
What is the difference between NSCLC and SCLC cell lines?
NSCLC cell lines model non-small cell lung cancers, primarily adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, while SCLC cell lines represent small cell lung cancer, a neuroendocrine malignancy with very different biology, mutation landscape, and treatment responses.
What are EGFR-mutant lung cancer cell lines?
EGFR-mutant lung cancer cell lines carry activating mutations in the epidermal growth factor receptor gene that make them sensitive to EGFR TKIs. The most commonly used are PC9 and HCC827 (both carrying exon 19 deletion) and H1975 (carrying L858R plus T790M).
What is the Lewis lung cancer cell line (LLC)?
The Lewis Lung Carcinoma (LLC) cell line is a syngeneic murine lung cancer line that grows in immunocompetent C57BL/6 mice.
Final Thoughts
There is no universal lung cancer cell line that fits every experimental question. A549 is a versatile and reliable general model but fails as an EGFR-targeted therapy model. PC9 and HCC827 are essential for TKI sensitivity studies but are not appropriate for KRAS research. LLC is irreplaceable for immune-competent in vivo work but should not be treated as a surrogate for human tumor biology.